Ketamine for Health & Longevity

Evidence Review created on 08/04/2026 using AI4L / Opus 5

Also known as: Esketamine, Arketamine, S-Ketamine, R-Ketamine, Ketamine Hydrochloride, Ketalar, Spravato, Special K

Motivation

Ketamine is an injectable anesthetic that has been used in operating rooms and emergency departments since the 1970s. At doses far below those used for surgery, it produces something unusual: a lift in mood that can appear within hours rather than the weeks required by standard antidepressants, and that seems to work by prompting nerve cells to rebuild connections with one another.

That observation, first reported in academic research in the 1990s, has since grown into an industry. A nasal form derived from ketamine was approved in the United States in 2019 for depression that has not responded to other treatments, and hundreds of private clinics now offer infusions, lozenges, and mail-order preparations. At the same time, ketamine has a long history of recreational use, and heavy users have developed serious bladder and liver damage.

This review examines what the human evidence shows about ketamine’s effects on mood, pain, and brain function, how large and how durable those effects are, whether its connection-building action holds anything for the aging brain, what harms have been documented at both therapeutic and heavy-use levels, and how the treatment is delivered and monitored in practice.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section collects high-level overviews of ketamine from clinicians and researchers who work with the compound directly.

• #220 ‒ Ketamine: Benefits, risks, and promising therapeutic potential – Celia Morgan, Ph.D. - Peter Attia

  A two-hour conversation with a psychopharmacologist who runs ketamine trials, covering neurobiology, how ketamine differs from classical psychedelics, and why pairing it with psychotherapy may matter more than the drug alone. It is the most balanced long-form treatment of both the promise and the abuse liability available from a longevity-oriented source.

• Ketamine: Benefits and Risks for Depression, PTSD & Neuroplasticity - Andrew Huberman

  A solo neuroscience episode that walks through the glutamate and opioid pathways underlying ketamine’s effects on mood and on PTSD (post-traumatic stress disorder, a persistent fear and arousal state following trauma), and compares routes of administration, dose ranges, and the different mirror-image forms of the molecule. Unusually rich on mechanism while still addressing recreational risk directly.

• Dr. John Krystal — All Things Ketamine, The Most Comprehensive Podcast Episode Ever (#625) - Tim Ferriss

  An interview with the Yale psychiatrist who led the original discovery of ketamine’s rapid antidepressant effect, covering the history of that finding, dosing, durability, and the difference between clinic-based and at-home models. Valuable as a primary account from the researcher who generated the founding data rather than a second-hand summary.

• Ketamine for treatment-resistant depression: When and where is it safe? - Peter Grinspoon

  A physician’s field report on the outpatient ketamine clinic industry, including what happened when the author telephoned several clinics posing as a prospective patient, plus concrete cost figures and the populations in whom ketamine is avoided. It is one of the few sources that examines the delivery system rather than only the molecule.

• RHR: The Emerging Field of Psychedelic-Assisted Psychotherapy, with Dr. Ingmar Gorman - Chris Kresser

  A functional-medicine conversation with the psychologist who co-led the pivotal trials of psychedelic-assisted psychotherapy, covering where ketamine sits alongside the classical psychedelics, how the preparation-dosing-integration structure around a single dose is built, and how the compounds differ in physiological safety. Its distinct value is the host’s own clinical account of watching ketamine reverse severe depression within a day, set against an explicit warning that none of these compounds is a cure-all.

Content from the priority experts Rhonda Patrick and Life Extension could not be included because neither has published a high-level overview of ketamine. FoundMyFitness carries two short single-study news items on ketamine and one psilocybin-focused interview in which it is discussed in passing, and Life Extension covers it only as a subsection of its depression protocol. Neither would give a reader a high-level understanding of the intervention.

Grokipedia

• Ketamine

  A long-form technical article covering the 1962 synthesis, the stereochemistry of the two mirror-image forms, receptor pharmacology, anesthetic and psychiatric indications, and the recreational-use and uropathy (urinary tract disease) literature. It is denser on chemistry and regulatory history than most consumer-facing references.

Examine

• Ketamine

  A short evidence-graded entry summarizing ketamine as a fast-acting anesthetic with pain-relieving, amnesic (causing short-term memory loss), anti-inflammatory, antidepressant, and hallucinogenic properties, categorized under brain health. Its value is mainly as a neutral scope check against the more enthusiastic clinic-marketing framing found elsewhere.

ConsumerLab

No ConsumerLab article on ketamine exists.

Ketamine is a prescription-only controlled medication rather than a dietary supplement, and ConsumerLab does not typically cover prescription medications, since its testing programme is built around over-the-counter supplement products.

Systematic Reviews

This section lists the highest-value systematic reviews and meta-analyses on ketamine identified through a direct PubMed search, prioritized by size, recency, journal standing, and relevance to the outcomes this review covers.

• Ketamine for the treatment of major depression: a systematic review and meta-analysis - Nikolin et al., 2023

  Pooled 49 randomized controlled trials (RCTs — studies in which participants are randomly assigned to the treatment or to a comparison condition) with 3,299 participants, and separated racemic ketamine from esketamine and high from low doses. It is the single most informative efficacy synthesis available, and it found the standard racemic infusion outperformed the approved nasal form on every timeframe examined.

• Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis - Fountoulakis et al., 2025

  A sceptical re-analysis of 87 esketamine papers, conducted under PRISMA (a standard checklist governing how systematic reviews must be reported), concluding that the effect on depression is weak though statistically real, that the effect on suicidal thinking is absent, and that several deaths during the registration programme deserve scrutiny. It is the strongest published counterweight to the manufacturer-sponsored esketamine literature.

• Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis - Rhee et al., 2022

  Compared ketamine head-to-head against electroconvulsive therapy (ECT — a procedure that induces a brief controlled seizure under anesthesia) across six trials and 340 patients, finding electroconvulsive therapy superior for acute symptom reduction with no difference in memory outcomes or serious adverse events. It anchors ketamine’s position relative to the established comparator for severe depression.

• Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability - Smith-Apeldoorn et al., 2022

  Synthesizes three RCTs, eight open-label trials, and 30 case series on repeated long-term dosing across intravenous, intranasal, oral, intramuscular, and subcutaneous routes. It is the key reference for the question that matters most to anyone considering ongoing rather than one-off use, and it reports that loss of response, cognitive impairment, addiction, and urinary problems appear uncommon in supervised maintenance.

• Systematic review and meta-analysis of ketamine-associated uropathy - Chan et al., 2022

  Pooled 45 studies covering 4,921 patients to quantify the bladder syndrome seen with heavy ketamine exposure, including symptom prevalence, bladder capacity, urine flow rates, and what camera inspection of the bladder and tissue samples showed. It is the definitive quantification of ketamine’s most feared long-term physical harm, and it establishes that abstinence is required for recovery.

Mechanism of Action

Ketamine’s actions are unusually multi-layered, and no single pathway explains the full effect profile.

• NMDA receptor blockade and the glutamate surge. Ketamine is a non-competitive, open-channel blocker of the N-methyl-D-aspartate receptor (NMDA — a docking site on nerve cells for glutamate, the brain’s principal excitatory signalling molecule). At subanesthetic doses (doses well below those that produce surgical anesthesia) it preferentially blocks NMDA receptors on fast-spiking inhibitory interneurons that use gamma-aminobutyric acid (GABA — the brain’s main calming signalling molecule). Removing that inhibitory brake causes a transient surge of glutamate release in the prefrontal cortex (the brain region governing planning and emotional regulation).

• AMPA receptor activation and synapse building. The glutamate surge activates AMPA receptors (a second, faster class of glutamate docking site), which triggers release of brain-derived neurotrophic factor (BDNF — a protein that keeps nerve cells alive and helps them form new connections). BDNF binds its receptor TrkB (the docking protein through which BDNF acts) and switches on mTOR (mechanistic target of rapamycin — a master control switch for cell growth and protein manufacture). Within 24 hours, animal studies show new dendritic spines (the physical contact points between nerve cells) appearing in the prefrontal cortex. This synaptogenesis hypothesis is the dominant explanation for why a drug cleared within hours produces effects lasting a week.

• The active metabolite pathway. Ketamine is converted to norketamine and then to hydroxynorketamines, of which (2R,6R)-hydroxynorketamine produces antidepressant-like effects in rodents without NMDA blockade and without dissociation (a sense of detachment from one’s body, surroundings, or sense of time), acting instead through AMPA receptors. This competing explanation implies the therapeutic effect and the psychoactive effect are separable — a claim that would reshape the field if confirmed in humans, but which has so far failed to replicate consistently in primate and human work.

• Opioid system involvement. A placebo-controlled crossover study found that pre-treating patients with naltrexone (an opioid-receptor blocker) abolished ketamine’s antidepressant effect while leaving dissociation intact, implying that mu-opioid receptor activity is necessary for the mood effect. Opponents argue the finding reflects naltrexone’s own mood effects and note that ketamine is not a direct opioid agonist. The dispute matters because an opioid-dependent mechanism would predict tolerance and dependence with repeated use.

• Lateral habenula burst-firing. Rodent work indicates ketamine silences burst firing in the lateral habenula (a small structure that suppresses reward circuitry and is hyperactive in depression). This offers a circuit-level rather than molecular-level account, and is not mutually exclusive with the synaptogenesis model.

• Key pharmacological properties. Ketamine exists in two mirror-image forms and is supplied as a racemate — an equal mixture of S-ketamine (esketamine, roughly three to four times more potent at the NMDA receptor) and R-ketamine (arketamine, less potent at NMDA but possibly longer-acting and less dissociative); the two forms are enantiomers (mirror-image versions of the same molecule). It is highly fat-soluble, crossing into the brain within seconds, with a volume of distribution of roughly 3 L/kg and plasma protein binding of about 12–50%. The distribution half-life is 10–15 minutes; the elimination half-life of the parent compound is 2–3 hours, while norketamine persists for around 12 hours and intranasal esketamine shows a terminal half-life of 7–12 hours. Metabolism takes place in the liver, primarily via CYP3A4 and CYP2B6 (liver enzymes that break down a large share of medications), with a minor contribution from CYP2C9. Bioavailability is 100% intravenously, roughly 90% intramuscularly, 25–50% intranasally, about 30% sublingually, and only 16–24% orally because of extensive first-pass liver metabolism — which is why oral dosing relies more heavily on norketamine exposure.

Historical Context & Evolution

• Original intended use. Ketamine was synthesized in 1962 at Parke-Davis as a shorter-acting, less hallucinogenic successor to phencyclidine, and was approved in the United States in 1970 as a general anesthetic. It became the field anesthetic of choice in the Vietnam War and remains on the World Health Organization’s list of essential medicines because, unlike most anesthetics, it preserves breathing and blood pressure and needs no oxygen supply or ventilator.

• The psychiatric turn. Yale investigators studying NMDA receptor function in schizophrenia observed in the 1990s that depressed patients given subanesthetic ketamine reported rapid mood improvement. A small crossover trial published in 2000 reported substantial reductions in depression scores within four hours, and replication at the National Institute of Mental Health in 2006 established the finding that reoriented depression research away from the monoamine (serotonin and noradrenaline) framework toward glutamate.

• What the historical findings actually showed. The founding trials were small — the 2000 study randomized seven patients — and unblinding was near-total because dissociation is obvious to participants. This is a genuine methodological limitation, and it is the core of the argument that effect sizes have been inflated by expectancy. It is not, however, a demonstration that the effect is absent: subsequent trials using active placebos such as midazolam have continued to show separation from control, though with smaller margins. Against that, the one trial that masked both arms under surgical anesthesia was small and found no separation from placebo at all — a result that sharpens the blinding question rather than settling it in either direction.

• The commercial and regulatory phase. Johnson & Johnson developed the S-enantiomer as an intranasal spray, which the FDA (the United States Food and Drug Administration, the agency that approves medicines) approved in 2019 for treatment-resistant depression and in 2020 for depression with acute suicidal ideation, under a restricted distribution programme requiring in-clinic administration and post-dose observation. Because generic racemic ketamine cannot be patented, almost no comparably funded trials of the intravenous form existed at that point — a funding asymmetry, not an evidence verdict, that shaped which form became reimbursable.

• The unsettled present. Two developments are pulling in opposite directions. A 2023 pragmatic trial in the New England Journal of Medicine found intravenous ketamine non-inferior to electroconvulsive therapy in non-psychotic treatment-resistant depression, while the meta-analysis by Rhee and colleagues had found electroconvulsive therapy superior; the discrepancy appears to turn on patient severity and on whether psychotic depression was included. Simultaneously, the 2025 esketamine re-analysis by Fountoulakis and colleagues argues the approved product’s benefit is modest and its suicidality benefit absent. Neither position should be read as final: the trials differ in population, blinding method, and endpoint timing, and the first well-powered independent head-to-head comparison of racemic ketamine against esketamine is still enrolling.

Expected Benefits

High 🟩 🟩 🟩

Rapid Reduction of Treatment-Resistant Depressive Symptoms

Subanesthetic ketamine lowers depression severity within hours in people whose depression has not responded to at least two adequate antidepressant courses — a condition termed treatment-resistant depression. The proposed mechanism is the glutamate-driven synaptic remodelling described above. The evidence base is a meta-analysis of 49 RCTs with 3,299 participants, supported by multiple independent syntheses and by a pooled patient-level analysis. The important nuance is durability: without repeat dosing, most of the benefit dissipates within one to two weeks, and the target population in every trial was clinically depressed patients, not people with normal mood seeking enhancement.

Magnitude: Standardized mean difference (a measure of effect size, where 0.2 is small, 0.5 moderate, and 0.8 large) of −0.73 (95% confidence interval, or CI — the range in which the true value most likely lies — of −0.91 to −0.56) for high-dose racemic ketamine immediately after the first infusion, corresponding to response rates of roughly 50–70% at 24 hours versus 10–25% on placebo.

Rapid Reduction in Suicidal Thinking ⚠️ Conflicted

Ketamine reduces the intensity of suicidal ideation within 24 hours, an effect that appears at least partly independent of the change in overall depression score. The mechanism is unclear but may involve rapid normalization of habenular and prefrontal activity. Evidence comes from an individual-participant meta-analysis of intravenous racemic ketamine trials and from a dedicated meta-analysis in unipolar and bipolar depression. The conflict is direct: the 2025 esketamine synthesis found no significant effect on suicidality at any timepoint for the approved nasal product, despite that product carrying a specific regulatory indication for depression with acute suicidal ideation.

Magnitude: In pooled intravenous data, roughly 55% of participants were free of suicidal ideation at day 1 versus about 20% on placebo; for intranasal esketamine, the pooled effect on suicidality was not statistically distinguishable from zero.

Perioperative Pain Relief and Opioid Sparing

Low-dose ketamine given around surgery reduces postoperative pain intensity and cuts the amount of opioid required, through NMDA blockade of the spinal wind-up process by which repeated pain signals amplify themselves. The evidence basis is a Cochrane systematic review of perioperative intravenous ketamine plus a large network meta-analysis of non-opioid analgesics (pain-relieving medications that are not opioids). The benefit is most pronounced in operations expected to be highly painful and in patients already tolerant to opioids; it is smaller and less consistent in minor procedures.

Magnitude: Roughly a 20–40% reduction in cumulative 24-hour morphine-equivalent consumption, with pain scores lowered by approximately 0.5–1.5 points on a 10-point scale.

Medium 🟩 🟩

Reduced Chronic and Neuropathic Pain

Ketamine infusions reduce pain in complex regional pain syndrome (a chronic limb pain condition with swelling and skin changes following injury) and in some neuropathic pain states, again through NMDA-mediated reversal of central sensitization (the process by which the spinal cord and brain become over-responsive to pain signals). The evidence is a meta-analysis of randomized trials of ketamine infusions for chronic pain, which found benefit but with substantial heterogeneity in dose, duration, and pain type. Relief typically outlasts the infusion by weeks rather than months, and repeat courses are usually required.

Magnitude: Mean pain reduction of approximately 1–2 points on a 10-point scale versus control, sustained for 2–12 weeks depending on protocol.

Reduction of Anxiety Symptoms

Ketamine reduces anxiety symptoms across diagnoses, including social anxiety and generalized anxiety, with onset within hours. The mechanism is presumed to overlap with the antidepressant pathway. A transdiagnostic systematic review and meta-analysis pooled the available controlled and open-label data and found a moderate effect, but the constituent trials were small, frequently unblinded, and heterogeneous in dose. Anxiety can also transiently worsen during the infusion itself before improving.

Magnitude: Pooled standardized mean difference of approximately −0.6 to −0.9 for anxiety symptom scales in the days following dosing.

Prevention and Reduction of Postpartum Depressive Symptoms

Low-dose ketamine or esketamine given around caesarean delivery reduces the incidence of depressive symptoms in the following weeks. The mechanism is presumed to be the same synaptic effect operating during a period of high vulnerability. Several meta-analyses of randomized trials, predominantly conducted in China, report consistent benefit, and one trial is following mothers to three years postpartum. The main limitation is geographic and methodological concentration, which raises questions about generalizability.

Magnitude: Relative reduction of roughly 40–50% in the proportion meeting a depression screening threshold at 4–6 weeks postpartum.

Reduced Post-Traumatic Stress Symptoms ⚠️ Conflicted

Repeated ketamine infusions reduce post-traumatic stress symptom severity, potentially by destabilizing consolidated fear memories so they can be updated. The evidence basis is a randomized controlled trial of six infusions over two weeks against midazolam as an active control, supported by smaller open-label series and rodent work on the nerve-cell traces that store a fear memory. That trial found meaningful effects but enrolled a small sample. The evidence is directly conflicted: a larger multi-site randomized trial in veterans and active-duty personnel with antidepressant-resistant post-traumatic stress disorder found no separation from midazolam at either dose tested, and the most plausible sources of the discrepancy are differences in population, symptom chronicity, and concurrent medication rather than in the drug itself. The largest ongoing trials are therefore testing ketamine as an add-on to exposure therapy rather than alone.

Magnitude: Approximately 11-point greater reduction on an 80-point clinician-rated trauma symptom scale versus active control in the positive trial, with about two-thirds of ketamine recipients classified as responders; in the larger multi-site trial the difference from active control was not statistically significant.

Reduced Heavy Drinking in Alcohol Use Disorder

A single ketamine infusion paired with memory-retrieval procedures or with brief psychological therapy reduces heavy drinking days in people with alcohol use disorder, plausibly by interfering with reconsolidation of reward-associated memories. The evidence is a phase 2 randomized trial with a factorial design plus supporting mechanistic studies. The finding is promising but rests on one moderately sized trial with several arms, and effects on total abstinence were less clear than effects on drinking quantity.

Magnitude: About a 16 percentage-point increase in days abstinent at six months (95% CI 3.8 to 28.1) for the combined ketamine-plus-therapy arm versus placebo plus alcohol education; about 10 percentage points for ketamine versus placebo overall.

Low 🟩

Rapid Improvement in Anhedonia

Ketamine reduces anhedonia (the loss of capacity to feel pleasure) sometimes independently of overall mood improvement, with imaging studies linking the change to increased glucose metabolism in reward-related circuitry. Evidence comes from secondary analyses of small National Institute of Mental Health crossover trials in treatment-resistant bipolar and unipolar depression rather than from dedicated adequately powered trials. Because anhedonia responds poorly to conventional antidepressants, this is a clinically interesting but under-tested signal.

Magnitude: Reductions of roughly 30–40% on anhedonia subscales within 24 hours in small crossover samples.

Reduction of Obsessive-Compulsive Symptoms

Single ketamine infusions produce rapid reductions in obsessive-compulsive symptoms in some patients, consistent with disordered glutamate signalling in the cortico-striatal circuits (the loops connecting the outer brain surface to the deeper movement- and habit-control structures) that drive repetitive behaviour. Evidence is limited to one small randomized crossover trial and several open-label series; effects were shorter-lived than in depression and a substantial minority did not respond at all. No maintenance protocol has been validated for this indication.

Magnitude: 50% of participants met response criteria at one week in the controlled crossover data, versus none on placebo.

Reduced Postoperative Depressive Symptoms and Delirium in Older Surgical Patients ⚠️ Conflicted

Intraoperative ketamine has been proposed to reduce postoperative depressive symptoms and post-surgical confusion in older adults, potentially through anti-inflammatory action on microglia (the brain’s resident immune cells). The evidence is directly conflicted: a meta-analysis of randomized trials found benefit for postoperative depression, and a 2024 meta-analysis found esketamine reduced neurocognitive disorders after surgery, while an earlier meta-analysis of intraoperative ketamine for delirium prevention found no effect. Trial populations, doses, and delirium assessment tools differ substantially, which is the most plausible source of the discrepancy.

Magnitude: Reported odds ratios (OR — how much more or less likely an outcome is with treatment than without, where 1.0 means no difference) for postoperative delirium range from approximately 0.6 (benefit) to 1.0 (no effect) across meta-analyses.

Speculative 🟨

Restoration of Synaptic Density in the Aging Brain

Loss of synapses in the prefrontal cortex is a feature of both depression and normal brain aging, and ketamine’s most distinctive property is rapid synaptogenesis in exactly that region. This has led to speculation that periodic dosing could offset age-related synaptic attrition in people without a psychiatric diagnosis. The basis is entirely mechanistic and preclinical: rodent studies showing dendritic spine regrowth within 24 hours, plus a small number of human imaging studies using synaptic vesicle protein tracers in depressed patients. No controlled study has examined cognitively healthy older adults, and no study of any design has measured a longevity or healthspan endpoint.

Anti-Inflammatory and Immune Modulation

Ketamine lowers circulating inflammatory signalling proteins including interleukin-6 and tumour necrosis factor alpha, and shifts macrophages (immune cells that clear debris and regulate inflammation) toward an anti-inflammatory state. Because chronic low-grade inflammation is implicated in most age-related disease, this raises the possibility of benefit beyond mood. The basis is mechanistic work plus small biomarker substudies within depression trials; no clinical outcome has been shown to follow from the biomarker change, and the effect has not been separated from the anti-inflammatory consequences of mood improvement itself.

Benefit-Modifying Factors

• BDNF Val66Met polymorphism. A common variant in the gene encoding brain-derived neurotrophic factor reduces activity-dependent release of that protein. Carriers of the Met allele have shown attenuated antidepressant response to ketamine in several trials, consistent with the BDNF-dependent mechanism, though replication is inconsistent and effect sizes are modest.

• CYP2B6 and CYP3A4 variants. Reduced-function variants of CYP2B6 (a liver enzyme that converts ketamine to norketamine) raise parent-drug exposure and may increase both effect and dissociation at a fixed dose, particularly with oral dosing where first-pass metabolism dominates. Pharmacogenetic testing is not routine and its clinical value has not been established prospectively.

• Baseline body mass index and inflammatory markers. Higher body mass index and elevated baseline C-reactive protein (a general marker of systemic inflammation) have both been associated with larger antidepressant responses in pooled patient-level analyses, suggesting an inflammation-linked responder subtype. Baseline BDNF and vitamin D levels have been examined as predictors with less consistent results.

• Sex differences. Women show somewhat higher plasma ketamine and norketamine concentrations at weight-adjusted doses and, in some analyses, greater antidepressant response — possibly reflecting oestrogen-related differences in synaptic plasticity, since preclinical work shows female rodents respond to lower doses. Sex-stratified analyses in human trials remain underpowered, and no sex-specific dosing is used clinically.

• Pre-existing health conditions. Comorbid anxiety disorders predict somewhat lower and less durable response. A personal or family history of alcohol use disorder has repeatedly predicted stronger antidepressant response, a counterintuitive finding thought to reflect shared NMDA receptor sensitivity. Bipolar depression responds similarly to unipolar depression, but with a small risk of switching into elevated mood.

• Age-related considerations. Response rates in adults over 65 are lower than in midlife adults in most trials, and older patients require lower doses for equivalent plasma concentrations because the liver clears the drug more slowly and lean body mass is lower. For a longevity-oriented reader at the older end of the target range, this means both the expected benefit and the effective dose are shifted downward, and blood pressure responses are more pronounced.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Acute Dissociation and Perceptual Distortion

Dissociation occurs in the majority of people at antidepressant doses and is the defining subjective effect of the treatment session. It arises directly from NMDA blockade in the outer brain surface and in the thalamus (the relay station that routes sensory signals to the rest of the brain). Evidence comes from every controlled trial, measured with a standardized dissociation rating scale, and from prescribing information for both products. It peaks around 40 minutes, resolves within one to two hours, and is the reason supervised administration and a post-dose observation period are mandatory for the approved nasal product.

Magnitude: Clinically meaningful dissociation in roughly 60–90% of recipients at 0.5 mg/kg intravenously; measurable dissociation scores in about 41–61% of esketamine recipients in registration trials.

Transient Blood Pressure and Heart Rate Elevation

Ketamine causes sympathetic activation, raising blood pressure and heart rate for roughly 40–90 minutes after dosing. The mechanism is inhibition of the reuptake of catecholamines (the body’s own stimulant signalling molecules, such as adrenaline) plus central sympathetic drive. This is documented in prescribing information for both products and in every safety meta-analysis. It is transient and self-limiting in healthy circulation, but it is the reason aneurysmal vascular disease and prior intracerebral bleeding are absolute contraindications, and why uncontrolled hypertension must be corrected before treatment.

Magnitude: Typical peak increases of 10–20 mmHg systolic and 5–15 mmHg diastolic; transient increases above 180/110 mmHg occur in roughly 3–8% of sessions.

Nausea and Vomiting

Nausea, and less often vomiting, is among the most common adverse effects, arising from ketamine’s action on the chemoreceptor trigger zone (the brainstem area that triggers vomiting in response to substances in the blood). It is reported consistently across depression, anesthesia, and emergency-medicine literature, and is dose-related. It is readily prevented or treated with standard antiemetic medication (medicines that suppress nausea and vomiting) and is the principal reason for fasting before infusions.

Magnitude: Nausea in approximately 25–35% and vomiting in roughly 5–10% of subanesthetic sessions.

Sedation, Dizziness, Headache, and Impaired Coordination

Sedation, vertigo, unsteadiness, and blurred vision occur in a large fraction of sessions as a direct consequence of central NMDA blockade and are the reason recipients cannot drive or operate machinery until the following day; headache is equally common and is attributed to the transient rise in blood pressure and cerebral blood flow. This is documented in prescribing information for both products and across the systematic review of side effects in depression treatment. Severity is dose- and rate-dependent: slower infusions produce markedly less. Headache usually begins as the acute effects fade and responds to simple analgesics, but it is one of the few effects that can carry into the following day. Recovery is otherwise complete within a few hours in essentially all cases.

Magnitude: Sedation in roughly 20–50%, dizziness in approximately 20–30%, and headache in roughly 20% of esketamine sessions against about 17% on placebo; driving restriction applies for at least 24 hours or until a full night’s sleep.

Urinary Tract Damage with Frequent High-Dose Use

Ketamine-associated uropathy is a progressive inflammatory destruction of the bladder lining producing urinary frequency, urgency, and suprapubic pain (pain low in the abdomen, just above the pubic bone), and in advanced cases contracted bladder capacity and kidney swelling. The mechanism involves direct toxicity to the urothelium (the cell layer lining the bladder) from ketamine and its breakdown products concentrated in urine. The evidence is a meta-analysis of 45 studies covering 4,921 patients, almost all heavy recreational users consuming gram-level daily doses. At supervised therapeutic frequencies the syndrome appears rare, but it is the harm that most clearly scales with cumulative exposure, and abstinence is required for recovery.

Magnitude: Among affected heavy users, pooled prevalence of urinary frequency 77.1% (95% CI 56.9–92.2), urgency 69.9%, suprapubic pain 60.4%, and kidney swelling 30.2%; mean functional bladder capacity reduced to about 95 mL against a normal 400–500 mL.

Medium 🟥 🟥

Misuse, Craving, and Dependence

Ketamine produces euphoria and is a recognized drug of misuse, and psychological dependence with escalating use has been documented. The mechanism plausibly involves the mu-opioid and dopaminergic contributions to its acute effects. Evidence comes from addiction epidemiology, from the systematic review of ketamine use, and from the abuse-potential warnings in the prescribing information for both products. The risk is concentrated in unsupervised at-home and mail-order models, and in people with a personal history of substance use disorder, which is why supervised administration and dispensing limits exist.

Magnitude: Craving and dose escalation reported in a minority of long-term therapeutic users; among recreational users, dependence estimates range from roughly 10% to over 30% of regular users.

Acute and Cumulative Cognitive Impairment ⚠️ Conflicted

Ketamine acutely impairs working memory, episodic memory, and attention during and shortly after dosing, and chronic heavy users show persistent deficits in episodic memory and executive function. The evidence is directly conflicted for therapeutic use: a systematic review of cognition in treatment-resistant depression patients receiving intravenous ketamine found neutral-to-improved cognition over repeated dosing, and the maintenance review found cognitive impairment uncommon, whereas studies of chronic recreational users show clear dose-related damage. The discrepancy is most plausibly explained by cumulative dose — recreational exposure is often 20–100 times the therapeutic monthly total — and by improvement in depression-related cognitive dysfunction masking any drug effect.

Magnitude: Acute working-memory decrements of roughly 0.5–1.0 standard deviations during infusion, resolving within hours; in heavy chronic users, episodic memory deficits of approximately 1.0 standard deviation persisting into abstinence.

Liver Enzyme Elevation and Bile Duct Injury

Repeated or high-dose ketamine can raise liver enzymes and, with heavy chronic use, produce dilatation of the bile ducts resembling sclerosing cholangitis (progressive scarring and narrowing of the bile ducts). The mechanism is thought to involve toxic metabolites and drug-induced smooth muscle effects on the biliary tree. Evidence comes from case series in chronic pain and recreational-use populations and from repeated-infusion protocols in which transient liver enzyme rises were observed. It is largely reversible on cessation if detected early, which is why liver monitoring is standard in maintenance protocols.

Magnitude: Transient liver enzyme elevations in roughly 5–15% of repeated-infusion courses; overt biliary abnormalities are largely confined to daily heavy users.

Loss of Response with Repeated Dosing

Some people require progressively higher doses or shorter intervals to maintain the same antidepressant effect, a pattern consistent with NMDA receptor adaptation and possibly with opioid-system tolerance. Evidence comes from maintenance case series and from the systematic review of maintenance treatment, which concluded that this outcome is uncommon but not absent. The practical consequence is the main reason clinicians cap session frequency and re-evaluate rather than escalate — and escalation is itself the pathway to the urinary and cognitive harms above.

Magnitude: Reported in an estimated 10–20% of people receiving maintenance dosing beyond six months.

Low 🟥

Worsening of Psychotic Symptoms in Susceptible Individuals

Because ketamine transiently reproduces features of psychosis in healthy volunteers, there is concern that it can precipitate or worsen psychotic symptoms in people with schizophrenia-spectrum illness or a strong family history. Evidence comes from the original NMDA-model-of-psychosis human studies and from case reports; controlled data are absent because such patients are excluded from trials. Symptoms in reported cases have generally been transient, but this exclusion is near-universal in clinical protocols.

Magnitude: Not quantified in available studies.

Emergent or Worsening Suicidal Thinking

Despite ketamine’s use for acute suicidality, a minority of patients experience emergent or worsening suicidal thinking, and the 2025 esketamine analysis specifically flagged deaths including suicides during the registration programme as warranting scrutiny. The mechanism is unclear and may reflect underlying illness severity rather than drug action, since the populations treated are at high baseline risk. This is a signal rather than an established causal effect, and it is the reason post-dose observation covers mental state as well as vital signs.

Magnitude: Six deaths including three suicides were recorded across the esketamine development programme, against a background population at very high baseline risk; no elevated rate versus comparator has been demonstrated.

Raised Intraocular and Intracranial Pressure ⚠️ Conflicted

Ketamine has long been described as raising pressure inside the eye and the skull, historically making it a relative contraindication in head injury and glaucoma. The evidence is directly conflicted: older anesthesia literature reported increases, whereas a recent systematic review and meta-analysis of ketamine in traumatic brain injury found no adverse effect on intracranial pressure and possible benefit for cerebral perfusion. The likely explanation for the discrepancy is that early studies used spontaneously breathing patients in whom carbon dioxide retention, not ketamine itself, raised pressure.

Magnitude: Modern controlled data show no significant change in intracranial pressure; older reports described transient rises of roughly 5–10 mmHg.

Speculative 🟨

Accelerated Brain Aging from Long-Term Repeated Exposure

Repeated NMDA blockade during brain development causes programmed nerve-cell death in animal models, and there is speculation that decades of periodic adult exposure could have cumulative structural consequences that current follow-up periods would miss. The basis is preclinical and mechanistic only: no human cohort has been followed on therapeutic ketamine for longer than a few years, and imaging studies in chronic recreational users cannot separate ketamine from polydrug use, nutrition, and lifestyle confounders. For a reader considering indefinite periodic dosing, this is the largest genuine unknown.

Gut Microbiome Alteration

Rodent studies show ketamine changes gut bacterial composition, and some of its antidepressant effect has been proposed to be microbiome-mediated. Whether the reverse holds — that repeated dosing degrades a favourable microbial profile in humans — has not been examined. The basis is isolated animal reports with no human data of any design.

Risk-Modifying Factors

• CYP2B6*6 and CYP3A5 variants. Reduced-function CYP2B6 alleles slow conversion of ketamine to norketamine, raising parent-drug exposure and thereby dissociation, blood pressure response, and sedation at a standard dose. CYP3A5 (a second liver enzyme, closely related to CYP3A4, that also breaks ketamine down) expression status similarly shifts exposure. Neither is tested routinely, so the practical safeguard remains starting low and titrating by observed response.

• Baseline blood pressure and liver enzymes. Pre-treatment blood pressure is the single most useful predictor of a problematic cardiovascular response, and pre-existing elevations of alanine aminotransferase or gamma-glutamyl transferase (liver enzymes that rise with liver stress) identify people in whom repeated dosing is more likely to cause further elevation. Baseline urinary symptoms similarly flag those with less bladder reserve.

• Sex differences. Women achieve higher plasma concentrations at the same weight-adjusted dose and report dissociation and nausea somewhat more frequently, while men are over-represented in ketamine use disorder and in uropathy case series — the latter reflecting recreational-use patterns rather than intrinsic susceptibility.

• Pre-existing health conditions. Uncontrolled hypertension, aneurysmal vascular disease, and prior intracerebral bleeding convert the transient pressor response (the short-lived rise in blood pressure after dosing) into a serious hazard. Schizophrenia-spectrum illness raises the risk of psychotic worsening; a history of substance use disorder raises misuse risk; moderate-to-severe liver impairment slows clearance and prolongs every effect; pre-existing bladder pathology lowers the threshold for urinary injury.

• Age-related considerations. Adults over 65 clear ketamine more slowly, have stiffer arteries that amplify the blood pressure response, and are at higher risk of falls during the post-dose unsteadiness window. They also more often take antihypertensives (blood-pressure-lowering medicines), sedatives, and anticoagulants (blood thinners) that interact with the effects above. For a reader at the older end of the target range, dose reduction and a longer supervised recovery period address most of this differential risk.

Key Interactions & Contraindications

• CYP3A4 and CYP2B6 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, ticlopidine, grapefruit juice). Severity: caution. These slow ketamine breakdown and raise plasma concentrations, intensifying dissociation, sedation, and blood pressure elevation. Mitigation: reduce the ketamine dose by roughly 25–50% or separate the interacting agent, and lengthen the observation period.

• CYP3A4 and CYP2B6 inducers (rifampicin, carbamazepine, phenytoin, efavirenz, St. John’s wort / Hypericum perforatum). Severity: caution. These accelerate breakdown and can render a standard dose ineffective while increasing norketamine exposure. Mitigation: avoid concurrent St. John’s wort, and expect that dose escalation may be needed with enzyme-inducing anticonvulsants.

• Benzodiazepines (calming and sleep-inducing medicines such as diazepam, lorazepam, clonazepam, alprazolam). Severity: caution, potentially efficacy-limiting. Multiple analyses show concurrent benzodiazepine use blunts and shortens ketamine’s antidepressant effect, probably by opposing the glutamate surge, while adding sedation. Mitigation: where clinically possible, taper before a course, or at minimum withhold the dose on treatment days.

• Lamotrigine and other glutamate-release inhibitors. Severity: monitor. Lamotrigine reduces presynaptic glutamate release and has been shown to attenuate ketamine’s psychoactive effects; it may also attenuate the therapeutic effect. Mitigation: no dose adjustment is established, but a diminished response should not automatically prompt dose escalation in people taking it.

• Opioid receptor antagonists (naltrexone, naloxone) — including low-dose naltrexone taken for other purposes. Severity: potentially efficacy-abolishing. Controlled data show naltrexone pre-treatment abolishes ketamine’s antidepressant effect while leaving dissociation intact. Mitigation: separate naltrexone dosing from ketamine sessions by at least 72 hours, or reconsider concurrent use.

• Central nervous system depressants (opioids, alcohol, gabapentinoids for nerve pain such as gabapentin and pregabalin, sedating antihistamines, sodium oxybate). Severity: caution to absolute avoidance in combination. Additive sedation and respiratory depression, and additive impairment of coordination. Mitigation: abstain from alcohol for 24 hours before and after, and avoid same-day opioid or sedative dosing.

• Monoamine oxidase inhibitors (an older class of antidepressants: phenelzine, tranylcypromine), stimulants (amphetamine, methylphenidate), thyroid hormone, and sympathomimetics (drugs that mimic the body’s own adrenaline signalling, such as pseudoephedrine). Severity: caution. Additive blood pressure and heart rate elevation, with potential for hypertensive urgency (a blood pressure spike high enough to require prompt treatment). Mitigation: check blood pressure before dosing and hold stimulant medication on treatment mornings.

• Theophylline and aminophylline. Severity: caution. Both lower the seizure threshold, and the combination with ketamine has been associated with seizure risk. Mitigation: avoid the combination where an alternative bronchodilator exists.

• Over-the-counter medications. Severity: mostly minor. Dextromethorphan (an NMDA-active cough suppressant) is additive with ketamine’s dissociative effects and is withheld on dosing days; sedating antihistamines such as diphenhydramine add to drowsiness; nonsteroidal anti-inflammatory drugs may modestly raise blood pressure in combination. Pseudoephedrine-containing decongestants add to the pressor response.

• Supplement interactions with additive effects. Severity: caution. Magnesium is itself an NMDA channel blocker and may be additive with ketamine’s central effects; agmatine and zinc likewise modulate NMDA receptors. Kava, valerian, melatonin, and 5-HTP (5-hydroxytryptophan, a serotonin precursor sold as a mood and sleep supplement) add sedation. High-dose caffeine amplifies the blood pressure and anxiety response. Cannabidiol inhibits CYP3A4 and can raise ketamine exposure. Mitigation: separate sedating supplements from dosing days and disclose all supplement use, as most are not asked about in clinic intake forms.

• Other intervention interactions. Severity: monitor. Ketamine has been used alongside electroconvulsive therapy as an anesthetic without clear added antidepressant benefit; combining it with psilocybin or other serotonergic psychedelics has no safety data. Sauna, cold exposure, and intense exercise on dosing days compound the cardiovascular load and the fall risk during the recovery window. Mitigation: schedule electroconvulsive therapy courses and ketamine courses separately rather than concurrently, avoid combining ketamine with other psychedelics until safety data exist, and keep heat, cold, and hard training off dosing days.

• Populations who should avoid ketamine. Absolute contraindications: aneurysmal vascular disease including thoracic, abdominal aortic, and intracranial aneurysms; arteriovenous malformation (an abnormal tangle of vessels connecting arteries directly to veins); any history of intracerebral haemorrhage; and known hypersensitivity. Avoid or defer in: uncontrolled hypertension (resting blood pressure above 180/110 mmHg); unstable angina or myocardial infarction within the preceding 6 weeks; New York Heart Association Class III–IV heart failure; severe liver impairment (Child-Pugh Class C, denoting advanced liver failure); active schizophrenia-spectrum psychosis; current moderate-to-severe substance use disorder involving ketamine, alcohol, or opioids; pre-existing interstitial cystitis (long-standing inflammation of the bladder wall causing pain and urinary frequency) or contracted bladder; pregnancy and breastfeeding; and untreated obstructive sleep apnoea when sedating routes are used. Use with heightened caution in adults over 75 and in anyone with a history of raised intracranial pressure.

Risk Mitigation Strategies

• Cardiovascular screening before the first dose: blood pressure measured on two separate occasions with treatment deferred above 180/110 mmHg, plus an electrocardiogram and consideration of aortic imaging in anyone over 60 or with a family history of aneurysm — this addresses the transient pressor response and the absolute contraindication of aneurysmal disease, the two mechanisms by which ketamine has caused catastrophic harm.

• Slow infusion and conservative starting dose: 0.5 mg/kg delivered over 40 minutes rather than as a bolus, with a first session at 0.3–0.5 mg/kg and escalation only if response is inadequate — slower delivery reduces peak plasma concentration and thereby the intensity of dissociation, sedation, nausea, and the blood pressure rise.

• Mandatory supervised observation: vital signs at baseline, 40 minutes, and before discharge, with a minimum 2-hour observation window and no discharge until dissociation has fully resolved — this catches hypertensive peaks and prevents falls and traffic incidents during the coordination-impairment window.

• Strict frequency capping: no more than twice-weekly during an induction course of up to six sessions, tapering to every 2–4 weeks for maintenance, with total exposure reviewed at six months — cumulative dose is the variable that drives bladder injury, bile duct injury, cognitive deficits, and dependence, so capping frequency is the single most effective control over all four.

• Quarterly urinary symptom screening: a structured question set on frequency, urgency, and suprapubic pain at every third session, with urinalysis and referral for cystoscopy (inspection of the bladder lining with a thin camera) if symptoms emerge — ketamine uropathy is reversible on cessation when caught early and irreversible when advanced, so early detection is the entire mitigation.

• Liver enzyme monitoring every 3–6 months during maintenance: discontinuation if alanine aminotransferase exceeds three times the upper limit of normal — this detects the liver enzyme elevations and bile duct changes that precede symptomatic biliary injury.

• Benzodiazepine taper before an induction course: where clinically safe, reducing benzodiazepine dose by 25% weekly to discontinuation before starting — this prevents the blunted and shortened antidepressant response documented with concurrent use, and avoids the temptation to escalate ketamine dose in response to an apparent non-response.

• Fasting and antiemetic pre-treatment: no solid food for 6 hours and no clear liquids for 2 hours before dosing, with ondansetron 4–8 mg given prophylactically to anyone who has vomited previously — this addresses nausea and vomiting and the aspiration risk that accompanies vomiting under sedation.

• Transport and next-day planning: a pre-arranged driver, no operation of vehicles or machinery for at least 24 hours or until after a full night’s sleep, and no safety-critical work the following day — this addresses residual sedation and impaired coordination.

• Avoiding unsupervised at-home and mail-order models for initial treatment: completing induction in a monitored setting before any consideration of take-home dosing, and never holding more than a single dose at home — unsupervised access is the documented route to dose escalation, dependence, and the harms that follow cumulative exposure.

• Screening and ongoing monitoring for misuse: a substance use history at intake and a standardized craving question at each session, with a written agreement that dose and frequency are set by the prescriber — this addresses the dependence risk that is highest in people with prior substance use disorder.

Therapeutic Protocol

• Standard intravenous induction protocol: 0.5 mg/kg of racemic ketamine in saline infused over 40 minutes, given twice weekly for three weeks (six sessions), then reassessed. This is the protocol used in the majority of academic trials and by academic-affiliated clinics, and derives directly from the National Institute of Mental Health work led by Carlos Zarate and from the Yale programme led by John Krystal and Gerard Sanacora. Non-responders after six sessions are generally not continued.

• Intranasal esketamine protocol: 56 mg for the first dose, then 56 or 84 mg twice weekly for four weeks, then weekly for four weeks, then every one or two weeks, always alongside a continuing oral antidepressant and always administered in a certified setting with two hours of observation. This is the regimen defined by Johnson & Johnson’s registration trials and mandated by the restricted distribution programme; note that the manufacturer both designed and funded the trials that established it.

• Sublingual and oral protocols: 50–300 mg of racemic ketamine as a rapidly dissolving lozenge (troche) held under the tongue for 10–15 minutes, typically two to three times weekly, or 0.5–3 mg/kg orally. Popularized by telehealth providers and by the ketamine-assisted psychotherapy community, this route is far less studied, produces lower and more variable plasma concentrations, and shifts exposure toward norketamine. It is presented here as a genuinely competing approach rather than a lesser version of the intravenous protocol, since its proponents argue the lower peak intensity is better suited to psychotherapy integration.

• Ketamine-assisted psychotherapy as a competing model: the same pharmacology delivered inside a preparation-dosing-integration structure, with a therapist present during the session and integration sessions afterwards. Advocated by clinicians associated with the Ketamine Research Foundation — an organization whose affiliated practitioners train and certify providers in this model and therefore derive direct revenue from its adoption — and by Celia Morgan’s group at Exeter for alcohol use disorder, this framework treats the drug as an adjunct to psychological work rather than as a standalone treatment. Head-to-head comparison against pharmacology-only delivery is limited, and neither model should be regarded as the default.

• Best time of day: morning to early afternoon dosing is standard, both because the acute stimulation can interfere with sleep if given late and because the required observation and recovery period runs several hours. No trial has systematically compared dosing times.

• Half-life considerations: with an elimination half-life of 2–3 hours for the parent compound and roughly 12 hours for norketamine, ketamine is fully cleared long before the antidepressant effect ends — the effect outlasts the drug by days, which is the strongest clinical argument that the benefit is mediated by structural change rather than by receptor occupancy.

• Single versus split dosing: the therapeutic effect appears to depend on achieving a threshold peak concentration, so a single delivered dose is standard and splitting is not used for intravenous or intranasal routes. The only routine exception is intranasal esketamine, where the dose is administered as two or three sprays five minutes apart to accommodate nasal absorption capacity, not to split exposure.

• Genetic polymorphisms influencing protocol: BDNF Val66Met carriers may respond less well, and reduced-function CYP2B6 variants raise exposure at a standard dose. Neither is tested routinely and neither has a validated dose adjustment; clinical titration by observed response remains the practical substitute.

• Sex-based differences in dosing: women reach higher plasma concentrations at identical weight-adjusted doses and may respond at lower doses; some clinicians start women at 0.3–0.4 mg/kg for this reason, though no trial has validated sex-specific dosing.

• Age-related considerations: adults over 65 are typically started at 0.25–0.4 mg/kg with slower titration because the liver clears the drug more slowly, lean mass is lower, and the vascular response is stiffer, and they are given a longer observation period because of fall risk. Response rates in this group are lower, so the threshold for discontinuing after a non-responsive induction course should not be raised simply because alternatives are limited.

• Baseline biomarkers influencing response: higher body mass index and elevated C-reactive protein predict better response in pooled analyses, and baseline blood pressure and liver enzymes determine the safe dose ceiling. These are used to set expectations and safety limits rather than to select candidates.

• Pre-existing conditions influencing response: a personal or family history of alcohol use disorder predicts stronger response; comorbid anxiety predicts weaker and shorter response; concurrent benzodiazepine use predicts blunted response and is the most common modifiable reason for apparent treatment failure.

Discontinuation & Cycling

• Lifelong versus short-term use: ketamine is not conceived as a permanent daily medication. The dominant model is an induction course followed either by discontinuation with reassessment, or by spaced maintenance at the longest interval that holds the benefit. The systematic review of maintenance treatment found supervised long-term dosing feasible but explicitly called the evidence insufficient to define its place in routine practice, so indefinite continuation remains an individual judgement rather than a validated protocol.

• Withdrawal effects: ketamine does not produce a physiological withdrawal syndrome comparable to alcohol or benzodiazepines, and no taper is needed on pharmacological grounds. Heavy chronic users report craving, low mood, sweating, tremor, and sleep disturbance on cessation, but these are features of dependence rather than of therapeutic discontinuation. Relapse of the underlying depression after stopping is common and should not be mistaken for withdrawal.

• Tapering-off protocol: where maintenance is being stopped, the standard approach is interval extension rather than dose reduction — moving from every two weeks to every three, then four, then six, monitoring symptom scores at each step — because the effect is threshold-dependent, so a reduced dose is more likely to produce no effect than a partial one.

• Cycling to maintain efficacy: deliberate drug holidays are not established practice, and there is no evidence that scheduled breaks restore diminished response. The relevant clinical practice is the opposite of cycling: since loss of response affects a minority and is not reliably reversed by escalation, a diminishing effect is usually treated as a signal to stop rather than to intensify. For anyone using ketamine outside a psychiatric indication, extended intervals are the only exposure-limiting tool available, since no minimum effective cumulative dose has been established.

Sourcing and Quality

• Pharmaceutical-grade product only: therapeutic ketamine is a licensed sterile injectable manufactured to an official published purity and potency standard and dispensed by a licensed pharmacy against a prescription. The reference brand is Ketalar (originated by Parke-Davis, now marketed by Pfizer), with therapeutically equivalent generic racemic vials from established sterile-injectable manufacturers such as Hikma and Fresenius Kabi; the only regulator-approved psychiatric presentation is Spravato intranasal esketamine from Janssen. Material obtained outside that chain is frequently adulterated — analyses of seized ketamine routinely find other dissociatives and cutting agents — and carries both dosing uncertainty and legal exposure as a controlled substance.

• Compounded formulations require particular scrutiny: under-the-tongue lozenges, nasal sprays, and rapid-dissolve tablets are compounded rather than manufactured under full regulatory oversight, and the FDA issued a specific 2023 warning about compounded ketamine products used for psychiatric conditions. What to look for: a compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board — long-established accredited compounders such as Empower Pharmacy and Belmar Pharma Solutions are examples of that tier — or an FDA-registered 503B outsourcing facility, plus documented potency and sterility testing on each batch and a stated beyond-use date.

• Formulation and enantiomer choice: the practical options are racemic ketamine (both mirror-image forms, used intravenously, intramuscularly, sublingually, and orally), esketamine (the S-form, the only version with regulatory approval for depression and the only one routinely reimbursed), and arketamine (the R-form, investigational only). Racemic ketamine is dramatically cheaper as a generic; esketamine is far more expensive but covered by insurance in many systems — a payer incentive structure that pushes toward the costlier product independently of comparative evidence, and one worth recognizing when a clinic presents one option as standard.

• Preservative content: multi-dose ketamine vials contain benzethonium chloride as a preservative. Preservative-free single-dose presentations are preferred where available, particularly for any route involving repeated mucosal exposure.

• Clinic and pharmacy selection: academic-affiliated and hospital-based programmes have consistently more safety infrastructure than free-standing commercial clinics, including physician screening, resuscitation equipment, and communication with the patient’s other clinicians. What to look for: a physician who reviews the full medical history before the first dose, on-site monitoring equipment, a written protocol for hypertensive events, and a stated policy on total cumulative exposure. Mail-order models that ship multiple doses without prior supervised sessions offer none of these.

Practical Considerations

• Time to effect: unusually fast. Mood improvement typically begins within 40 minutes to 4 hours of the first dose and peaks at 24 hours; where a full induction course is needed, maximum benefit is usually reached by the fourth to sixth session, roughly two to three weeks in. Pain benefits appear during the infusion itself. Absence of any response after two properly dosed sessions predicts poorly for the remainder of the course.

• Duration of effect: the corresponding limitation. A single dose typically holds for three to fourteen days; a completed six-session course holds a median of two to four weeks before relapse in most trials, with a minority sustaining remission for months. This gap between rapid onset and short duration is the central practical problem of ketamine therapy and the driver of every maintenance protocol.

• Common pitfalls: continuing benzodiazepines through an induction course and concluding the treatment failed; escalating dose or frequency in response to fading benefit rather than reassessing; treating dissociation intensity as a marker of therapeutic effect when the two correlate poorly; using at-home sublingual dosing as the entry point rather than after supervised induction; and neglecting to arrange the psychological or lifestyle work that determines whether a two-week window of increased plasticity is used for anything.

• Regulatory status: racemic ketamine is a Schedule III controlled substance in the United States and a Class B controlled drug in the United Kingdom, approved as an anesthetic; all psychiatric and chronic-pain use of racemic ketamine is off-label. Esketamine nasal spray is approved for treatment-resistant depression and for depression with acute suicidal ideation, and is dispensed only through a restricted programme requiring on-site administration and observation. Compounded oral and sublingual products occupy a lightly regulated space that the FDA has explicitly warned about.

• Cost and accessibility: intravenous infusions typically cost $400–800 each in the United States and are rarely covered by insurance, putting a six-session induction course at roughly $2,400–4,800 out of pocket; esketamine costs roughly $600–900 per dose but is frequently reimbursed because of its approved status, while the generic drug itself costs a few dollars per vial. Telehealth sublingual programmes run $200–400 monthly. Access outside major metropolitan areas is limited, and the observation requirement makes each session a half-day commitment.

Interaction with Foundational Habits

• Sleep: direct and bidirectional. Ketamine acutely increases slow-wave sleep and raises brain-derived neurotrophic factor overnight, and the magnitude of that slow-wave increase has predicted antidepressant response in several studies — which is the mechanistic argument for protecting the night after dosing. In the opposite direction, dosing late in the day can delay sleep onset because of residual stimulation. Practical considerations: sessions are scheduled before early afternoon, alcohol and cannabis are avoided on the dosing night since both suppress slow-wave sleep, and the following night’s sleep is treated as part of the protocol rather than as incidental to it.

• Nutrition: indirect, with two direct constraints. Fasting for 6 hours before dosing is required to reduce aspiration risk with vomiting, and grapefruit juice is excluded because it inhibits CYP3A4 and raises ketamine exposure. Beyond that, no diet has been shown to modify response, though adequate protein and the substrate availability needed for synapse formation are a plausible if unproven consideration during the plasticity window. Practical considerations: the main meal falls after the observation period rather than before the session, and high-dose magnesium supplementation is separated from dosing days given its own NMDA activity.

• Exercise: potentiating in principle, cautionary in timing. Aerobic exercise raises brain-derived neurotrophic factor through the same signalling pathway ketamine engages, and animal work suggests the two are additive for synaptic growth — making exercise during the post-dose plasticity window a rational, if untested, pairing. The direct constraint is that exercise on the day of dosing compounds the cardiovascular load and the coordination impairment. Practical considerations: training is omitted on dosing days and resumed the following day, and meaningful training is concentrated within the two-week window when plasticity is elevated.

• Stress management: direct and mechanistically central. Chronic stress drives the synaptic loss in the prefrontal cortex that ketamine acutely reverses, so an unchanged stressor environment predicts a faster return to baseline; conversely, the post-dose period of elevated plasticity is when psychotherapy, meditation practice, and behavioural change appear most likely to take hold, which is the core rationale for ketamine-assisted psychotherapy. Ketamine also acutely raises cortisol during the session itself. Practical considerations: psychological work is scheduled within 24–72 hours of dosing rather than weeks later, and the plasticity window rather than the drug is treated as the intervention.

Monitoring Protocol & Defining Success

Baseline testing establishes both eligibility and a comparison point: before a first dose, protocols measure blood pressure on two separate occasions and obtain a full metabolic panel, liver panel, complete blood count, and urinalysis, together with an electrocardiogram in anyone over 50 or with cardiac history. Liver enzymes are reported as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and alkaline phosphatase (ALP); kidney function is reported as estimated glomerular filtration rate (eGFR — a calculated measure of how well the kidneys filter blood). Symptom severity is recorded with a validated depression scale before the first session.

Ongoing monitoring follows a defined cadence: vital signs at every session; symptom scales at every session and at 24 hours after the first; liver panel, kidney function, and urinalysis at 1 month, then every 3 months during active maintenance, and every 6 months once dosing is spaced beyond monthly; and a structured cognitive and urinary symptom review every 6 months.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Blood pressure	110–125 / 70–80 mmHg resting	Defines eligibility and predicts the acute pressor response	Conventional criteria treat anything below 130/80 mmHg as acceptable; the functional target is tighter because the acute rise is added on top of the resting value. Two seated readings on separate days; treatment deferred above 180/110 mmHg. Re-check at 40 minutes and before discharge each session
Alanine aminotransferase (ALT)	10–26 U/L (women), 10–33 U/L (men)	Detects the liver enzyme elevation seen with repeated dosing	Conventional laboratories flag only above 40–55 U/L; functional practitioners act on the tighter range. Fasting preferred, and avoid intense exercise for 48 hours before
Gamma-glutamyl transferase (GGT)	Below 20 U/L	Most sensitive early marker of biliary stress and of concurrent alcohol use	Conventional upper limit is 50–65 U/L. Rises before alkaline phosphatase in ketamine-associated bile duct injury; best paired with ALT and alkaline phosphatase
Estimated glomerular filtration rate (eGFR)	Above 90 mL/min/1.73 m²	Confirms kidney reserve before repeated exposure and detects obstruction from bladder disease	Conventional laboratories flag only below 60 mL/min/1.73 m²; functional practitioners act on the tighter threshold. Cystatin C-based estimation is preferred in people with high muscle mass. Pair with urinalysis and, where symptoms exist, renal ultrasound for kidney swelling
Urinalysis with microscopy	No blood, no white cells, no protein	Earliest objective signal of bladder lining injury	Midstream clean-catch sample. Sterile blood or white cells in urine without infection is the classic early finding and warrants urological referral
C-reactive protein, high-sensitivity	Below 1.0 mg/L	Baseline inflammation predicts a larger antidepressant response and tracks the anti-inflammatory signal	Conventional cardiovascular risk stratification calls anything below 3.0 mg/L acceptable; the functional target is roughly threefold tighter. Postpone if any acute illness in the preceding 2 weeks, since transient infection invalidates the reading. Draw fasting alongside the metabolic panel
Depression symptom score (validated scale)	Below 10 on a 27-point self-report scale	The primary efficacy endpoint against which continuation is judged	Record before the first dose, at 24 hours, and before each subsequent session; time of day is kept constant, as mood varies substantially across the day
Dissociation score (validated scale)	Peak below 20, returning to baseline by 2 hours	Confirms the expected acute effect and defines safe discharge	Measured at 40 minutes and before discharge. Poorly correlated with antidepressant response, so it should not be used to titrate dose upward

Qualitative markers matter as much as laboratory values here, because the outcomes that define success are subjective:

• Anhedonia: whether previously enjoyable activities regain their pull, often the first thing to change and frequently ahead of overall mood score.
• Rumination: whether repetitive negative thought loops become interruptible rather than automatic.
• Sleep quality and continuity: particularly early-morning waking, which often resolves before daytime mood does.
• Cognitive clarity: subjective processing speed and word-finding, tracked as a safety signal as much as a benefit — decline over months of maintenance is a reason to stop.
• Energy and initiation: the capacity to begin tasks rather than the capacity to complete them, which distinguishes genuine improvement from transient stimulation.
• Urinary comfort: frequency, urgency, and any suprapubic discomfort, asked about explicitly at every third session rather than left for the patient to volunteer.
• Craving and clock-watching: any sense of anticipating the next session for its own sake, which is the earliest behavioural marker of developing dependence.

Emerging Research

• Independent head-to-head comparison of racemic ketamine against esketamine: a Yale-led, patient-centred comparative effectiveness trial (NCT06713616, phase 3, 400 participants, primary endpoint self-reported effectiveness) is the first well-powered study funded outside the manufacturer to compare the two forms directly. Its result could either confirm the meta-analytic signal that racemic ketamine outperforms the approved product, or overturn it — this is the single trial most likely to change how the field is organized, in either direction.

• Comparative effectiveness of two ketamine forms in treatment-resistant depression: an Australian trial run by The George Institute (NCT06278779, phase 4, 162 participants, primary endpoint the Montgomery-Åsberg Depression Rating Scale) provides a second, geographically independent test of the same question in a public-health-system setting.

• Ketamine added to time-limited psychological treatment for post-traumatic stress disorder: a Yale trial (NCT05737693, phase 2, 162 participants) pairs ketamine with a week-long exposure therapy protocol against midazolam plus the same therapy, with amygdala activation as a mechanistic endpoint. This directly tests the plasticity-window hypothesis that underpins ketamine-assisted psychotherapy — and a null result would substantially weaken it.

• Low-dose esketamine for delirium in high-risk older surgical patients: the ELEMENT trial (NCT06817239, 1,670 participants, primary endpoint delirium incidence within 5 days) is by far the largest study addressing whether ketamine protects the aging brain around a major physiological stressor, and is the most directly relevant ongoing trial for a longevity-oriented reader.

• Arketamine as a non-dissociative alternative: an intranasal R-ketamine spray is in phase 2 testing for depression with acute suicidal ideation (NCT07193901, 98 participants). An earlier phase 2 trial of the same enantiomer by Perception Neuroscience (NCT05414422, 102 participants) failed to separate from placebo on its primary endpoint — evidence pointing against the claim that the therapeutic effect can be cleanly separated from the dissociative one, and a result that argues for caution about the whole non-dissociative programme.

• Long-term cumulative exposure and cognition: the question that most needs resolution for anyone contemplating years of periodic dosing has no dedicated prospective trial. The available evidence remains a systematic review, Cognitive changes in patients with unipolar TRD treated with IV ketamine: A systematic review - Grasso et al., 2024 (TRD — treatment-resistant depression; IV — intravenous, meaning delivered into a vein), reporting neutral-to-favourable findings over months, set against cross-sectional work such as Cognitive impairment in chronic ketamine abusers - Zhang et al., 2020, showing clear deficits in heavy users. Until a cohort is followed on therapeutic maintenance for a decade, the extrapolation between those two bodies of evidence is unresolved in both directions.

• Separating drug effect from expectancy: trials using surgical anesthesia to mask both arms — the design used in Randomized trial of ketamine masked by surgical anesthesia in patients with depression - Lii et al., 2023 — and the wider debate about active placebos, will determine how much of the observed effect survives genuine blinding. Work in this direction could substantially shrink the estimated effect size; the counter-argument, that dissociation is not correlated with response and therefore cannot be the mechanism of unblinding, has not been settled either.

• Metabolite-based compounds: hydroxynorketamine and related molecules are in early human testing as potential antidepressants without dissociation or abuse liability, with the first-in-human safety and pharmacokinetic assessment reported in A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers - Raja et al., 2024. Positive results would make ketamine itself largely obsolete for psychiatric use; negative results would strengthen the case that the psychoactive experience is not separable from the benefit.

Conclusion

Ketamine occupies an unusual position: a decades-old anesthetic that, at much lower doses, reliably lifts severe low mood faster than any other available treatment. The strongest human evidence covers depression that has resisted other treatments, short-term relief of suicidal thinking, and pain control around surgery. Effects on longer-standing pain, anxiety, trauma symptoms, and heavy drinking are supported by smaller and less consistent studies. Nothing in the evidence base speaks directly to lifespan or to healthy people seeking cognitive or mood optimization; the synapse-rebuilding effects that make it interesting from a brain-aging perspective have been shown mainly in animals and in short human studies.

The harms are well characterized and dose- and frequency-dependent. Short sessions under supervision produce brief distortions of perception, raised blood pressure, and nausea that resolve the same day. Frequent heavy use, largely documented outside medicine, produces bladder scarring, bile duct injury, memory problems, and craving. Benefit fades in many people once dosing stops, which pushes toward repeated exposure — exactly the pattern linked to the serious harms.

The evidence base carries notable financial entanglement. Most trials of the approved nasal form were funded by its manufacturer, most infusion clinics are for-profit and unregulated, and the professional bodies that publish guidance draw members from those clinics. Much of what is known about long-term use comes from observation rather than controlled comparison.

Top - Benefits - Risks - Protocol